Pharmacologic Inhibition of YAP/TEAD and Development of New Chorioretinal Atrophy
Downregulation of the Hippo signaling pathway via YAP/TEAD inhibition in an adult patient may result in a phenotype resembling a mild form of HPCD (Sveinsson chorioretinal atrophy), underscoring the importance of this pathway in maintenance of the adult retina and retinal pigment epithelium. As novel cancer therapeutics continue to emerge, it may be important to ensure ophthalmologic monitoring of patients on drugs targeting the Hippo pathway.
Authors
- Paul G. Arrigg (ORCID: https://orcid.org/0000-0001-9399-614X)
- Dean Eliott (ORCID: https://orcid.org/0000-0002-7699-1053)
- Isaac D. Bleicher (ORCID: https://orcid.org/0000-0002-5221-8998)
- Aaron Nagiel (ORCID: https://orcid.org/0000-0001-7275-6980)
- Edward S. Lu (ORCID: https://orcid.org/0000-0002-1281-156X)
- David J. Kwiatkowski (ORCID: https://orcid.org/0000-0002-5668-5219)
- Mohamed Ashraf (ORCID: https://orcid.org/0000-0003-4231-2566)
- Lindsay K. Kozek
Institutions
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Massachusetts Eye and Ear Infirmary (US)
- Joslin Diabetes Center (US)
- Beth Israel Deaconess Medical Center (US)
- Children's Hospital of Los Angeles (US)
- Harvard University (US)
- Southern California Eye Institute (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JAMA Ophthalmology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1001/jamaophthalmol.2025.4213
- Citations
- 2
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 2.30